ResearcherUniversity of VeronaActive in the last 2 years
Giuseppe Toffoli
Matched on ORCID iD 0000-0002-5323-4762; OpenAlex author ID A5068048791. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 9
2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 2 papers
Papers 7
- The anti-GPC1 antibody AT101 as effective targeting agent for chemotherapeutic-loaded chitosan nanobubbles in the treatment of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.biopha.2026.119956↗
- PLGA/PVA nanoparticles to deliver a protein-based cancer vaccine targeting GPC1 for the treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/17435889.2026.2676617↗
- Antigenic Dark Matter: Unexplored Post-Translational Modifications of Tumor-Associated and Tumor-Specific Antigens in Pancreatic Cancer. Last author DOI 10.3390/cancers17213506↗
- Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer. Co-author DOI 10.3390/medicina61040633↗
- A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12967-023-04745-9↗
- The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/ijms231810279↗
- Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. Co-author DOI 10.3748/wjg.v23.i32.5875↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Davide Busato · 5 shared papers, 2022–2026 · strength 1.24
- Paper Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreat… DOI 10.3390/medicina61040633↗
- Paper PLGA/PVA nanoparticles to deliver a protein-based cancer vaccine targeting GPC1 for the treatment of pancreatic ductal … DOI 10.1080/17435889.2026.2676617↗
- Paper The anti-GPC1 antibody AT101 as effective targeting agent for chemotherapeutic-loaded chitosan nanobubbles in the treat… DOI 10.1016/j.biopha.2026.119956↗
- Amin Safa · 3 shared papers, 2025–2026 · strength 0.97
- Paper Antigenic Dark Matter: Unexplored Post-Translational Modifications of Tumor-Associated and Tumor-Specific Antigens in P… DOI 10.3390/cancers17213506↗
- Paper Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreat… DOI 10.3390/medicina61040633↗
- Paper PLGA/PVA nanoparticles to deliver a protein-based cancer vaccine targeting GPC1 for the treatment of pancreatic ductal … DOI 10.1080/17435889.2026.2676617↗
- Idris Vruzhaj · 3 shared papers, 2025–2026 · strength 0.97
- Paper Antigenic Dark Matter: Unexplored Post-Translational Modifications of Tumor-Associated and Tumor-Specific Antigens in P… DOI 10.3390/cancers17213506↗
- Paper Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreat… DOI 10.3390/medicina61040633↗
- Paper PLGA/PVA nanoparticles to deliver a protein-based cancer vaccine targeting GPC1 for the treatment of pancreatic ductal … DOI 10.1080/17435889.2026.2676617↗
- Marta Gambirasi · 3 shared papers, 2025–2026 · strength 0.97
- Paper Antigenic Dark Matter: Unexplored Post-Translational Modifications of Tumor-Associated and Tumor-Specific Antigens in P… DOI 10.3390/cancers17213506↗
- Paper Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreat… DOI 10.3390/medicina61040633↗
- Paper PLGA/PVA nanoparticles to deliver a protein-based cancer vaccine targeting GPC1 for the treatment of pancreatic ductal … DOI 10.1080/17435889.2026.2676617↗
- Michele Dal Bo · 4 shared papers, 2022–2026 · strength 0.93
- Paper PLGA/PVA nanoparticles to deliver a protein-based cancer vaccine targeting GPC1 for the treatment of pancreatic ductal … DOI 10.1080/17435889.2026.2676617↗
- Paper The anti-GPC1 antibody AT101 as effective targeting agent for chemotherapeutic-loaded chitosan nanobubbles in the treat… DOI 10.1016/j.biopha.2026.119956↗
- Paper The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ducta… DOI 10.3390/ijms231810279↗
- Monica Argenziano · 1 shared paper, 2026 · strength 0.24
- Massimo Pancione · 1 shared paper, 2017 · strength 0.07
- Guido Giordano · 1 shared paper, 2017 · strength 0.07
- Mario Rosario D'Andrea · 1 shared paper, 2017 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.